<DOC>
	<DOCNO>NCT00971932</DOCNO>
	<brief_summary>The primary objective trial assess antitumor activity cetuximab give combination cisplatin + 5-Fluorouracil ( 5-FU ) first-line treatment recurrent and/or metastatic squamous cell carcinoma head neck ( SCCHN ) Japanese subject .</brief_summary>
	<brief_title>Study Cetuximab Combination With Chemotherapy Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma Head Neck ( SCCHN )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . Histologically cytologically confirm diagnosis SCCHN 2 . Confirmed epidermal growth factor receptor ( EGFR ) expression tumor tissue immunohistochemistry ( IHC ) 3 . Expected survival 6 month 4 . Presence least 1 bidimensionally measurable lesion either compute tomography ( CT ) scan magnetic resonance imaging ( MRI ) 5 . Recurrent and/or metastatic SCCHN suitable local therapy 6 . Greater equal ( &gt; = ) 20 year age 7 . Karnofsky performance status ( KPS ) &gt; = 70 % trial entry 8 . Neutrophils : &gt; = 1500 per millimeter^3 ( 1,500/mm^3 ) ; platelet count &gt; = 100,000/mm^3 ; hemoglobin &gt; = 9 gram per deciliter ( g/dL ) 9 . Total bilirubin less equal ( &lt; = ) 2 * upper limit normal ( ULN ) ; aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; = 3 * ULN 10 . Creatinine clearance &gt; 60 milliliter per minute ( mL/min ) .Calculated base formula CockroftGault formula creatinine clearance 11 . Serum calcium within normal range ( If serum albumin &lt; 4.0 g/dL , follow adjust serum calcium concentration within normality : Adjusted serum calcium concentration = actual serum calcium ( milligram per deciliter [ mg/dL ] ) 0.8 * [ actual serum albumin ( g/dL ) 4 ] 12 . Effective contraception risk conception exists ( applicable male female subject ) 13 . Signed write informed consent 14 . Japanese ( Japanese citizenship ) 1 . Nasopharyngeal carcinoma 2 . Prior systemic chemotherapy , except give part multimodal treatment , complete 6 month prior trial entry 3 . Surgery ( exclude prior diagnostic biopsy ) irradiation within 4 week trial entry 4 . Pregnancy ( absence confirm serum/urine human chorionic gonadotropin [ HCG ] test ) breastfeed 5 . Known hypersensitivity allergic reaction component trial treatment include excipients 6 . Uncontrolled diabetes , malignant hypertension ( define systolic blood pressure &gt; = 180 millimeter mercury [ mmHg ] and/or diastolic blood pressure &gt; = 130 mmHg rest condition ) liver failure 7 . Pulmonary fibrosis , acute lung injury interstitial pneumonia , previous medical history state 8 . Active infection , ( infection require IV antibiotic , antibacterial , antifungal , antiviral agent ) , include active tuberculosis , know declared human immunodeficiency virus ( HIV ) 9 . Clinically relevant coronary artery disease history myocardial infarction last 12 month high risk uncontrolled arrhythmia uncontrolled cardiac insufficiency 10 . Current squamous cell carcinoma ( SCC ) previous malignancy ( exclude skin cancer except melanoma carcinoma situ cervix digestive tract ) within last 5 year 11 . Intake investigational medication within 30 day trial entry 12 . Other concomitant anticancer therapy 13 . Documented symptomatic brain leptomeningeal metastasis 14 . Medical psychological condition would permit subject complete trial sign inform consent include know drug abuse 15 . Previous treatment monoclonal antibody therapy , signal transduction inhibitor EGFR target therapy 16 . Legal incapacity limit legal capacity 17 . Other protocoldefined exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Recurrent and/or metastatic</keyword>
	<keyword>SCCHN</keyword>
</DOC>